Table 2.

Subgroup analysis of the association between patient age and antibiotic resistance in CRKP

Antibiotic	Subgroup	Studies (k)	Pooled resistance rate (95% CI)	I2 (%)a		Qb	P
Levofloxacin	0–17 years	9	0.02 (0.00–0.14)	77		62.82	< 0.010
	18–59 years	14	0.92 (0.76–0.99)	61
	≥ 60 years	16	0.95 (0.83–1.00)	86
Amikacin	0–17 years	10	0.04 (0.00–0.22)	79		26.55	< 0.010
	18–59 years	16	0.81 (0.60–0.95)	87
	≥ 60 years	22	0.70 (0.43–0.90)	91
Gentamicin	0–17 years	8	0.14 (0.01–0.40)	77		19.95	< 0.010
	18–59 years	6	0.89 (0.61–1.00)	94
	≥ 60 years	14	0.86 (0.65–0.98)	81
Ciprofloxacin	0–17 years	8	0.22 (0.00–0.68)	84		18.11	< 0.010
	18–59 years	9	0.90 (0.60–1.00)	69
	≥ 60 years	20	1.00 (0.98–1.00)	0
Colistin	0–17 years	5	0.00 (0.00–0.00)	0		7.64	0.020
	18–59 years	10	0.00 (0.00–0.02)	0
	≥ 60 years	13	0.10 (0.00–0.42)	83
Nitrofurantoin	0–17 years	2	0.25 (0.00–0.79)	39		7.15	< 0.010
	≥ 60 years	2	1.00 (0.92–1.00)	0
Aztreonam	0–17 years	10	0.81 (0.44–1.00)	77		6.45	0.040
	18–59 years	13	1.00 (0.99–1.00)	50
	≥ 60 years	15	0.97 (0.87–1.00)	73

^a The random-effects model was used to calculate the pooled resistance rate due to high heterogeneity